Latest Systemic scleroderma Stories
DANVERS, Mass., Aug. 4 /PRNewswire-USNewswire/ -- The Scleroderma Foundation applauds Senator Kirsten Gillibrand (D-NY) for introducing S. 1545, the "Scleroderma Research and Awareness Act" in the United States Senate.
DANVERS, Mass., July 16 /PRNewswire/ -- The Scleroderma Foundation, the nation's leading non-profit supporter of scleroderma research, is holding the Gateway to Hope 2009 National Patient Education Conference July 17-19, 2009 in St. Louis, Missouri.
DANVERS, Mass., May 15 /PRNewswire/ -- The Scleroderma Foundation applauds Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI) for introducing H.R. 2408, the "Scleroderma Research and Awareness Act" in the House of Representatives today.
DANVERS, Mass., Oct.
arGentis Pharmaceuticals, LLC announced today that it has filed a patent application for Nucleic Acid Sequences highly associated with the inability of oral immune tolerance to be induced in some systemic sclerosis (SSc) patients.
arGentis Pharmaceuticals, LLC announced today that the Phase II results using highly purified type 1 bovine collagen orally (now known as ARG201) in the treatment of diffuse cutaneous systemic sclerosis (scleroderma - SSc) have been published in the June issue of Arthritis & Rheumatism, a major peer-reviewed rheumatology research journal.
SOUTH SAN FRANCISCO, Calif.
By Park, Joo Hun; Kim, Dong Soon; Park, I-Nae; Jan
It's called scleroderma, a disfiguring disorder that causes the skin and internal organs to harden and tighten. Yet few people have heard of or know much about it.
ABSTRACT: The purpose of this study was to identify hand factors that change over a five-year period that may be risk factors for the development of functional disability in persons with systemic sclerosis (scleroderma).